Vascular dementia

American Thoracic Society Selects Vasomune Therapeutics, Inc., to Present the AV-001 Development Update at the 2024 Respiratory Innovation Summit

Retrieved on: 
星期一, 四月 15, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, TEK tyrosine kinase, H3N2, Pneumonia, Safety, Sepsis, Survival, HVR, Conference, Stroke, PEGylation, Disease, Acute kidney injury, Therapy, Patient, RIS, Death, American Thoracic Society, Vascular dementia, Infection

Activation of this receptor plays a critical role in vascular stability, barrier integrity and endothelial quiescence, particularly within the pulmonary space.

Key Points: 
  • Activation of this receptor plays a critical role in vascular stability, barrier integrity and endothelial quiescence, particularly within the pulmonary space.
  • Vasomune’s Scientific co-founder, Dr. Harold Kim, will speak on May 18th, at 11:30 AM PT, at the Manchester Grand Hyatt, San Diego, CA.
  • “We are extremely excited to be invited to present our work at the Respiratory Innovation Summit during the American Thoracic Society 2024 Conference.
  • Join Dr. Kim at the Respiratory Innovation Summit to learn how Vasomune Therapeutics has brought together decades of research to create AV-001, a clinical-stage candidate for the treatment of diseases associated with vascular dysfunction.

MEDITWIN Brings Together French Science and Technology Excellence Around Virtual Twins for the Future of Medical Care

Retrieved on: 
星期三, 一月 24, 2024
Data Management, Other Science, Technology, Research, Telemedicine, Virtual Medicine, Manufacturing, Other Health, Apps, Applications, Oncology, Medical Devices, Health Technology, Hospitals, Biometrics, Cardiology, Other Technology, Biotechnology, Software, Health, Science, Electronic Design Automation, PRISM, Teaching hospital, Biology, Morphometrics, Artificial intelligence, Ventricular septal defect, ICM, Thorax, Living Brain, Molina Healthcare, Test management, INRIA, Cerebral atrophy, Foresight, Medicine, Cancer, Algorithm, Risk, Dravet syndrome, Diagnosis, Cardiovascular disease, System, Cardiac arrest, Epilepsy, SAFIR, Alzheimer's disease, Safety, Cognition, CHU, Metabolism, Neurology, Dassault Group, Public, Artificiality, IHU, Hypoplastic left heart syndrome, Mortality, Patient, EEG, Partnership, Consciousness, Ecosystem, Digital, Vascular dementia, PEPR, Biomarker, Medical imaging

MEDITWIN will offer virtual twins for medical practice, helping to improve the quality of care for safer, more accessible healthcare for all.

Key Points: 
  • MEDITWIN will offer virtual twins for medical practice, helping to improve the quality of care for safer, more accessible healthcare for all.
  • The MEDITWIN project will offer personalized virtual twins of organs, metabolism and cancer, for better diagnosis and treatment.
  • Seven new medical practices will be developed from the virtual twins, in neurology, cardiology and oncology.
  • The MEDITWIN public-private alliance is a major step forward, mobilizing the best of medicine, science and technology to serve future healthcare.

SLT (CognivAiD™) Improves Memory and Cognition in Individuals With Mild Cognitive Impairment: Clinical Trial Results

Retrieved on: 
星期四, 十一月 9, 2023
Ageing, MCI, Therapy, Thought, Professor, Greater Western Sydney, Function (mathematics), Risk, Vascular dementia, Neurology, SLT, VAD, Patient, Diagnosis, Memory, Pharmaceutical industry, Computer data storage, Dementia

Investigator-initiated clinical trial of SLT (CognivAiD™) for mild cognitive impairment, led by Western Sydney University’s NICM Health Research Institute.

Key Points: 
  • Investigator-initiated clinical trial of SLT (CognivAiD™) for mild cognitive impairment, led by Western Sydney University’s NICM Health Research Institute.
  • Trial results reported that CognivAiD™ significantly improved key cognitive domains of episodic memory and executive function, and was well-tolerated.
  • SINGAPORE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Moleac, a biopharmaceutical company pioneering innovative therapeutics in neurology, announced promising results from an investigator-led clinical trial conducted on SLT (CognivAiD™) in mild cognitive impairment (MCI).
  • Individuals with MCI are at increased risk of developing dementia later on.

Danny Bonaduce's "Mystery Illness" Explained

Retrieved on: 
星期二, 六月 6, 2023
Vascular dementia, Intraparenchymal hemorrhage, AARP, Ageing, Encephalitis, History, Suite, Incidence, Nursing, Alzheimer's disease, Dementia, Patient, Institutionalisation, Hydrocephalus, Diagnosis, Trauma, Family, NPH, Urinary incontinence, Medical imaging

Hydrocephalus Association, 4340 East West Highway, Suite 905, Bethesda, Maryland 20814, June 06, 2023 (GLOBE NEWSWIRE) -- Danny Bonaduce’s recent battle with a “mystery illness” and lack of diagnosis occurs all too frequently.

Key Points: 
  • Hydrocephalus Association, 4340 East West Highway, Suite 905, Bethesda, Maryland 20814, June 06, 2023 (GLOBE NEWSWIRE) -- Danny Bonaduce’s recent battle with a “mystery illness” and lack of diagnosis occurs all too frequently.
  • Patients with normal pressure hydrocephalus (NPH) (estimated to be close to 1 million in the U.S.) present with symptoms of gait disorder, urinary incontinence, and dementia.
  • These people are often misdiagnosed with Parkinson’s or Alzheimer’s Disease, vascular dementia, or even normal aging, due to their chronic nature and nonspecific presenting symptoms.
  • An AARP article (December 2013) described NPH as follows: “The condition mimics Alzheimer's, but it's far more treatable”.

QuantalX Receives FDA Breakthrough Designation for Diagnosis of Normal Pressure Hydrocephalus and Prediction of Treatment Response

Retrieved on: 
星期二, 五月 30, 2023
CT, Vascular dementia, Prevalence, Shunt (electrical), DSM-IV codes, Stroke, Quality of life, Alzheimer's disease, Delphi, Cerebrospinal fluid, Dementia, KFAR, MRI, Science, Medtronic, Walking, VPS, Parkinson's disease, Patient, Risk, Physician, Diagnosis, Entrepreneurship, CSF, FDA, Health, NPH, Pharmaceutical industry, Medical imaging, Neuromodulation

KFAR SABA, Israel, May 30, 2023 /PRNewswire/ -- QuantalX, the developer of Delphi-MD, a novel point-of-care neurodiagnostic device, has announced that they have received the prestigious FDA breakthrough designation medical device status for another clinical application, Normal Pressure Hydrocephalus (NPH). The FDA recognized the innovative value of the device in diagnosing NPH patients and predicting the response to the recommended treatment for NPH, ventriculoperitoneal shunting (VPS) surgery.

Key Points: 
  • The FDA grants the Delphi-MD device breakthrough designation technology status for the diagnosis of Normal Pressure Hydrocephalus (NPH) patients and prediction of response to highly effective, ventriculoperitoneal shunting surgery (VPS) treatment.
  • KFAR SABA, Israel, May 30, 2023 /PRNewswire/ -- QuantalX, the developer of Delphi-MD, a novel point-of-care neurodiagnostic device, has announced that they have received the prestigious FDA breakthrough designation medical device status for another clinical application, Normal Pressure Hydrocephalus (NPH).
  • The FDA recognized the innovative value of the device in diagnosing NPH patients and predicting the response to the recommended treatment for NPH, ventriculoperitoneal shunting (VPS) surgery.
  • This marks the second time that the Delphi-MD device has been granted a breakthrough designated medical device by the FDA.

Global Psychiatry Partnering Deal Trends, Players and Financials Directory/Report 2016-2023 - ResearchAndMarkets.com

Retrieved on: 
星期二, 三月 14, 2023
Biotechnology, Pharmaceutical, Health, Mental Health, Tardive dyskinesia, Chapter Five, A-Z, Chapter Six, Chronic fatigue syndrome, Bulimia nervosa, Tourette syndrome, Chapter Two, Research, Sleep disorder, Alzheimer's disease, Vascular dementia, Personality disorder, Confidentiality, Learning disability, Sleep apnea, Anxiety disorder, Three-body problem, Eating disorder, Cognitive deficit, Psychiatry, Chapter One, Panic disorder, Obsessive–compulsive disorder, Hyperlink, Intellectual property, Collection, Attention deficit hyperactivity disorder, Chapter Four, Chapter Three, Bipolar disorder, Narcolepsy, Directory, Pharmaceutical industry, Lease, Risk management, Commercial property, Property management, Anorexia nervosa, Dystonia, Akathisia, Autism spectrum, Dementia, Insomnia, Depression, Schizophrenia, Delirium

The "Global Psychiatry Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Psychiatry Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
  • The report takes readers through the comprehensive psychiatry disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering psychiatry deals.
  • Chapter 6 provides a comprehensive directory of all psychiatry partnering deals by specific psychiatry target announced since 2016.
  • In addition, a comprehensive appendix is provided with each report of all psychiatry partnering deals signed and announced since 2016.

Neurophet to unveil new technology for analyzing ARIA side effect at ECR 2023

Retrieved on: 
星期四, 三月 2, 2023
European, Prognosis, Multimedia, Congress, MRI, FDA, AI, Myenteric plexus, Dementia, Edema, Observation, PET, Radiology, WMH, ECR, Patient, European Congress of Radiology, AQUA, Health, SWI, ARIA, LAB, Atrophy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Multiple sclerosis, Diagnosis, Vascular dementia, Biomarker, Food, Bleeding, GRE, Artificial intelligence, Brain, Medical device, Medical imaging, Pharmaceutical industry, Lecanemab, Alzheimer's disease

Neurophet SCALE PET is an AI-based PET image analysis software that quantifies PET tracer bindings automatically.

Key Points: 
  • Neurophet SCALE PET is an AI-based PET image analysis software that quantifies PET tracer bindings automatically.
  • Neurophet is carrying out the ATNV Project, a national research project using the flagship products Neurophet AQUA and Neurophet SCALE PET funded by Korea dementia research center.
  • Monitoring and management of ARIA are essential for prescribing anti-amyloid antibody drugs, and it seems to be possible to analyze ARIA through Neurophet's ATNV project technology.
  • He added, "The vascular neuropathology quantification technology for analyzing WMH and ARIA-H could also be used to diagnose multiple sclerosis, and the technology is being advanced."

Moleac launches CognivAiD™, a novel targeted product for vascular dementia

Retrieved on: 
星期一, 一月 16, 2023
Saffron, Acetylcholinesterase, Caregiver, Vascular dementia, Safety, Neurology, Medical Affairs Bureau, Memantine, Vad, Patient, Research, Dementia, NMDA, Incidence, Pharmaceutical industry, Moleac

CognivAiD provides a long-awaited option to fulfil the unmet needs of patients with vascular dementia.

Key Points: 
  • CognivAiD provides a long-awaited option to fulfil the unmet needs of patients with vascular dementia.
  • SINGAPORE, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Moleac announced on 29th October 2022 the launch of CognivAiD™, the first-in-market specific product for Vascular Dementia (VaD).
  • David Picard, CEO of Moleac, commented on the launch: “Moleac focuses on neurology to help patients reconnect with their lives.
  • Vascular dementia, the second most common subtype of dementia after Alzheimer’s disease, accounts for 15-30% of all dementia cases 2 .

Dementia Drugs Market Predicted to Reach USD 19.7 Billion, Globally, by 2031 at 8.5% CAGR: Says Allied Market Research

Retrieved on: 
星期一, 十二月 12, 2022
Online, Vascular dementia, Geriatrics, Cholinesterase, Conditional sentence, Diagnosis, Drug discovery, Hospital, Dementia, Parkinson's disease dementia, Prevalence, Patient, NMDA, Smoker, Research, COVID-19, Drug development, Pharmacy, Government, Combination, Investment, Growth, Receptor antagonist, Life expectancy, Distribution, Pharmacy Council of India, Consciousness, Medical device, Pharmaceutical industry, Alzheimer's disease

PORTLAND, Ore., Dec. 11, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, "Dementia Drugs Market by Indication (Lewy Body Dementia, Parkinsons Disease Dementia, Alzheimers Disease, Vascular Dementia, Other Indications), by Drug Class (Cholinesterase Inhibitors, NMDA Antagonists and its Combination Drugs), by Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031". According to the report, the global dementia drugs industry generated $8.7 billion in 2021, and is anticipated to generate $19.7 billion by 2031, witnessing a CAGR of 8.5% from 2022 to 2031.

Key Points: 
  • However, strict government regulations related to product approval and high cost linked to R&D activity restrain the growth of dementia drugs industry.
  • Conversely, accelerated technological advancement in drug discovery techniques and high investment for drug development by the government are expected to offer lucrative opportunity for the dementia drugs market in future.
  • The outbreak of the Covid-19 pandemic had a positive impact on the global dementia drugs market, as it was reported that the pandemic caused a significant rise in the number of dementia patients.
  • Thus, increase in COVID-19 infection in patients with Alzheimer's disease increased the demand for dementia drugs during the pandemic.

Dementia Drugs Market Predicted to Reach USD 19.7 Billion, Globally, by 2031 at 8.5% CAGR: Says Allied Market Research

Retrieved on: 
星期一, 十二月 12, 2022
Online, Vascular dementia, Geriatrics, Cholinesterase, Conditional sentence, Diagnosis, Drug discovery, Hospital, Dementia, Parkinson's disease dementia, Prevalence, Patient, NMDA, Smoker, Research, COVID-19, Drug development, Pharmacy, Government, Combination, Investment, Growth, Receptor antagonist, Life expectancy, Distribution, Pharmacy Council of India, Consciousness, Medical device, Pharmaceutical industry, Alzheimer's disease

PORTLAND, Ore., Dec. 11, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, "Dementia Drugs Market by Indication (Lewy Body Dementia, Parkinsons Disease Dementia, Alzheimers Disease, Vascular Dementia, Other Indications), by Drug Class (Cholinesterase Inhibitors, NMDA Antagonists and its Combination Drugs), by Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031". According to the report, the global dementia drugs industry generated $8.7 billion in 2021, and is anticipated to generate $19.7 billion by 2031, witnessing a CAGR of 8.5% from 2022 to 2031.

Key Points: 
  • However, strict government regulations related to product approval and high cost linked to R&D activity restrain the growth of dementia drugs industry.
  • Conversely, accelerated technological advancement in drug discovery techniques and high investment for drug development by the government are expected to offer lucrative opportunity for the dementia drugs market in future.
  • The outbreak of the Covid-19 pandemic had a positive impact on the global dementia drugs market, as it was reported that the pandemic caused a significant rise in the number of dementia patients.
  • Thus, increase in COVID-19 infection in patients with Alzheimer's disease increased the demand for dementia drugs during the pandemic.